The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
Subscribe To Our Newsletter & Stay Updated
